Chenqi Xu


2022.04.27 16:00-17:30


Cancer immunotherapy has become a new frontline of cancer treatment. The representative therapies include Immune Checkpoint Blockade (ICB) therapy (2018 Nobel Prize) and CAR-T cell therapy. The fact that the ICB drug will become the No. 1 worldwide best-selling drug reflects the tremendous potential of cancer immunotherapy. The basic principles of cancer immunotherapy are the harnessing of natural antitumor functions of human immune cells. However, cancer cells can develop sophisticated mechanisms to suppress immune cells and thus to achieve immune evasion. This seminar will introduce the basic principles of cancer immunotherapy and discuss current challenges and future directions. 


Chenqi Xu is now a principle investigator at Shanghai Institute of Biochemistry (SIBCB), Chinese Academy of Sciences. He started his independent career at the end of 2009 and his laboratory has made original discoveries in T cell biology, including illustrating the electrostatic regulation model of immunoreceptor signaling and the critical function of cholesterol in antitumor immunity. He also develops new strategies of cancer immunotherapy, which have been successfully licensed out to biotech companies. His representative publications include Cell 2020, Immunity 2020, Nature 2018, Nature 2016 and Nature 2013. Two of his works were selected as “10 Science Breakthroughs of China of Year 2016” and “10 Life Science Breakthroughs of China of Year 2016 and Year 2020”. He now serves as an editorial board member of Cell Research, Life Metabolism and JBC. Given his outstanding contributions to the field, he received several prestigious awards such as the Chinese Youth Award of Science and Technology, Shanghai Distinguished Youth Award of Science and Technology, Chinese Academy of Sciences Young Scientist Award, Wuxi AppTec Award of Outstanding Achievement in Life Chemistry.